<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Thromb J</journal-id><journal-id journal-id-type="iso-abbrev">Thromb J</journal-id><journal-title-group><journal-title>Thrombosis Journal</journal-title></journal-title-group><issn pub-type="epub">1477-9560</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27980462</article-id><article-id pub-id-type="pmc">5134224</article-id><article-id pub-id-type="publisher-id">121</article-id><article-id pub-id-type="doi">10.1186/s12959-016-0121-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Edoxaban versus enoxaparin for the prevention of venous thromboembolism after total knee or hip arthroplasty: pooled analysis of coagulation biomarkers and primary efficacy and safety endpoints from two phase 3 trials</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Kawai</surname><given-names>Yohko</given-names></name><address><phone>+81 3 3402 3151</phone><email>yohko@iuhw.ac.jp</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Fuji</surname><given-names>Takeshi</given-names></name><address><phone>+81 6 6441 5451</phone><email>fuji-th@umin.ac.jp</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Fujita</surname><given-names>Satoru</given-names></name><address><phone>+81 7 9784 8811</phone><email>fujita@takarazuka-daiichi-hp.or.jp</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Kimura</surname><given-names>Tetsuya</given-names></name><address><phone>+81 3 6225 1111</phone><email>kimura.tetsuya.d2@daiichisankyo.co.jp</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Ibusuki</surname><given-names>Kei</given-names></name><address><phone>+81 90 2732 9505</phone><email>ibusuki.kei.tx@daiichisankyo.co.jp</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Abe</surname><given-names>Kenji</given-names></name><address><phone>+81 3 5740 3422</phone><email>abe.kenji.v7@daiichisankyo.co.jp</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Tachibana</surname><given-names>Shintaro</given-names></name><address><phone>+81 3 3711 5771</phone><email>s-tachi@mishuku.gr.jp</email></address><xref ref-type="aff" rid="Aff6">6</xref></contrib><aff id="Aff1"><label>1</label>International University of Health and Welfare, 8-10-16 Akasaka, Minato-ku, Tokyo 107-0052 Japan </aff><aff id="Aff2"><label>2</label>Department of Orthopaedic Surgery, Japan Community Healthcare Organization Osaka Hospital, 4-2-78, Fukushima, Fukushima-ku, Osaka 553-0003 Japan </aff><aff id="Aff3"><label>3</label>Department of Orthopaedic Surgery, Takarazuka Daiichi Hospital, 19-5 Kogetsu-cho, Takarazuka, 665-0832 Japan </aff><aff id="Aff4"><label>4</label>Daiichi Sankyo Co., Ltd, 3-5-1, Nihonbashi Honcho, Chuo-ku, Tokyo 103-8426 Japan </aff><aff id="Aff5"><label>5</label>Clinical Data &#x00026; Biostatistics Department, Daiichi Sankyo Co. Ltd, 1-2-58, Hiromachi, Shinagawa-ku, Tokyo 140-8710 Japan </aff><aff id="Aff6"><label>6</label>Department of Orthopaedic Surgery, Mishuku Hospital, 5-33-12 Shimomeguro, Meguro-ku, Tokyo 153-0051 Japan </aff></contrib-group><pub-date pub-type="epub"><day>1</day><month>12</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>12</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>14</volume><elocation-id>48</elocation-id><history><date date-type="received"><day>31</day><month>3</month><year>2016</year></date><date date-type="accepted"><day>8</day><month>11</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>The objective of this analysis was to assess the effects of edoxaban compared with enoxaparin on key coagulation biomarkers and present pooled primary efficacy and safety results from phase 3 STARS E-3 and STARS J-V trials for prevention of venous thromboembolism (VTE) after total knee arthroplasty (TKA) or total hip arthroplasty (THA).</p></sec><sec><title>Methods</title><p>In the randomized, double-blind, double-dummy, multicenter, STARS E-3 and STARS J-V trials, patients received edoxaban 30&#x000a0;mg or enoxaparin 2000&#x000a0;IU (20&#x000a0;mg) twice daily for 11 to 14&#x000a0;days. The studies were conducted in Japan and Taiwan; enoxaparin dosing was based on Japanese label recommendations. The primary efficacy endpoint was incidence of VTE; the safety endpoint was major or clinically relevant nonmajor (CRNM) bleeding. Blood samples were taken at presurgical evaluation, pretreatment (postsurgery), predose on day 7, predose on completion of treatment, and at a follow-up examination 25 to 35&#x000a0;days after the last dose of study drug for D-dimer, prothrombin fragment 1&#x02009;+&#x02009;2 (F<sub>1+2</sub>), and soluble fibrin monomer complex (SFMC) measurement.</p></sec><sec><title>Results</title><p>A total of 716 patients enrolled in STARS E-3 and 610 patients enrolled in STARS J-V; 1326 patients overall. This analysis included 657 patients who received edoxaban 30&#x000a0;mg QD and 650 patients who received enoxaparin 20&#x000a0;mg BID. Incidence of VTE was 5.1 and 10.7% for edoxaban and enoxaparin, respectively (<italic>P</italic> &#x0003c;0.001). Incidence of combined major and CRNM bleeding was 4.6 and 3.7% for edoxaban and enoxaparin, respectively (<italic>P</italic>&#x02009;=&#x02009;0.427). On day 7, mean D-dimer (4.4 vs 5.5&#x000a0;&#x003bc;g/mL), F<sub>1+2</sub> (363 vs 463 pmol/L), and SFMC (5.7 vs 6.8&#x000a0;&#x003bc;g/mL) were lower in edoxaban-treated patients relative to enoxaparin-treated patients, respectively (<italic>P</italic> &#x0003c;0.0001 for all). At end of treatment, mean D-dimer (5.4 vs 6.2&#x000a0;&#x003bc;g/mL), F<sub>1+2</sub> (292 vs 380 pmol/L), and SFMC (6.2 vs 7.2&#x000a0;&#x003bc;g/mL) were lower in edoxaban-treated patients relative to enoxaparin-treated patients (<italic>P</italic> &#x0003c;0.0001 for all).</p></sec><sec><title>Conclusions</title><p>Edoxaban was superior to enoxaparin in prevention of VTE following TKA and THA, with comparable rates of bleeding events. Relative to enoxaparin, edoxaban significantly reduced D-dimer, F<sub>1+2</sub>, and SFMC.</p></sec><sec><title>Trial registration</title><p>Clintrials.gov <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01181102">NCT01181102</ext-link> and <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01181167?term=NCT01181167&#x00026;rank=1">NCT01181167</ext-link>. Both registered 8/12/2010.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/s12959-016-0121-1) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>DOAC</kwd><kwd>Total knee arthroplasty</kwd><kwd>Total hip arthroplasty</kwd><kwd>Biomarker</kwd><kwd>VTE prophylaxis</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002336</institution-id><institution>Daiichi Sankyo Company</institution></institution-wrap></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Background</title><p>Patients undergoing orthopedic surgery such as total knee arthroplasty (TKA) or total hip arthroplasty (THA) are at high risk for venous thromboembolism (VTE) [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Anticoagulation therapy and/or mechanical prophylaxis, including compression stockings or intermittent pneumatic compression, are recommended for prevention of VTE after orthopedic surgery [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. In Japan, edoxaban [<xref ref-type="bibr" rid="CR3">3</xref>], a direct oral anticoagulant (DOAC) selective inhibitor of activated factor Xa (FXa), and enoxaparin [<xref ref-type="bibr" rid="CR4">4</xref>], an injectable low-molecular-weight heparin (LMWH), are both indicated for prophylaxis of deep vein thrombosis (DVT) following TKA, THA, or hip fracture surgery. The approval of edoxaban for the primary prevention of VTE after lower limb orthopedic surgery was based on evidence collected during three phase 3 studies evaluating the safety and efficacy of edoxaban compared with enoxaparin for prevention of VTE in Japanese or Taiwanese patients following TKA [<xref ref-type="bibr" rid="CR5">5</xref>], THA [<xref ref-type="bibr" rid="CR6">6</xref>], and hip fracture surgery [<xref ref-type="bibr" rid="CR7">7</xref>]. In these studies, edoxaban demonstrated significantly reduced or comparable rates of VTE and similar rates of bleeding events relative to enoxaparin.</p><p>This report presents a post hoc pooled analysis of coagulation biomarkers in the TKA/THA studies as well as pooled results of the primary efficacy (VTE) and safety (bleeding events) endpoints. Coagulation biomarkers include D-dimer, prothrombin fragments 1&#x02009;+&#x02009;2 (F<sub>1+2</sub>), and soluble fibrin monomer complex (SFMC). D-dimer, which has a high negative predictive value for VTE, is formed upon cleavage of cross-linked fibrin polymers by plasmin [<xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref>]. F<sub>1+2</sub> is a marker of thrombin generation and represents coagulation activity [<xref ref-type="bibr" rid="CR11">11</xref>]. Fibrin monomers result from cleavage of fibrinogen by thrombin [<xref ref-type="bibr" rid="CR8">8</xref>]. Soluble fibrin in plasma is also a marker of coagulation activity and is seen to increase rapidly during and after hip replacement surgery [<xref ref-type="bibr" rid="CR12">12</xref>]. Assessment of coagulation biomarkers can provide information on the effect of anticoagulants in relation to dose and clinical response.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><p>Detailed descriptions of the methodology of these trials are available in the primary publications (STARS E-3 [<xref ref-type="bibr" rid="CR5">5</xref>] and STARS J-V [<xref ref-type="bibr" rid="CR6">6</xref>]). The trial designs for patients undergoing TKA (STARS E-3; NCT01181102) or THA (STARS J-V; NCT01181167) were similar. In the randomized, double-blind, double-dummy, multicenter trials, patients received oral edoxaban 30&#x000a0;mg or edoxaban placebo once daily within 6 to 24&#x000a0;h after surgery, and subcutaneous enoxaparin 2000&#x000a0;IU (equivalent to 20&#x000a0;mg) or enoxaparin placebo twice daily within 24 to 36&#x000a0;h after surgery, each for 11 to 14&#x000a0;days. Enoxaparin 20&#x000a0;mg is the usual recommended dose for adults in Japan due to the lower body weight of Japanese patients [<xref ref-type="bibr" rid="CR13">13</xref>]; standard of care is administration of enoxaparin 24 to 36&#x000a0;h postsurgery.</p><p>Concomitant use of anticoagulants, antiplatelet agents, thrombolytic agents, or other agents that affect thrombus formation was not allowed from the day of surgery until 24&#x000a0;h after the final dose of study drug, unless treatment of deep vein thrombosis or pulmonary embolism (PE) was required. Mechanical prophylaxis (eg, elastic stockings or intermittent pneumatic compression therapy of the foot sole or lower leg and thigh) was permitted from the day of surgery to venography. Venography of the operated lower limb in the TKA trial STARS E-3 and of both lower limbs in the THA trial STARS J-V was performed within 24&#x000a0;h of the last dose of study drug or within 96&#x000a0;h in exceptional cases such as difficulty establishing an intravenous line.</p><p>The studies were performed in accordance with the provisions of the Declaration of Helsinki, Guidelines for Good Clinical Practice, and other related regulations. The protocols were approved by institutional review boards at each study center, and written informed consent was obtained from all patients prior to randomization.</p><sec id="Sec3"><title>Patients</title><p>Men and women 20 to &#x0003c;85&#x000a0;years of age undergoing unilateral TKA or THA (both excluding revision arthroplasty) were included. Presurgical exclusion criteria included risk for bleeding, risk for thromboembolism, previous TKA, weight &#x0003c;40&#x000a0;kg, severe renal impairment (creatinine clearance &#x0003c;30&#x000a0;mL/min) [<xref ref-type="bibr" rid="CR14">14</xref>], evidence of hepatic dysfunction (serum aspartate aminotransferase or serum alanine aminotransferase levels &#x02265;2 times the upper limit of normal or total bilirubin &#x02265;1.5 times the upper limit of normal), previous treatment with edoxaban, and current antithrombotic therapy for another complication. Postsurgical exclusion criteria included abnormal bleeding from the puncture site during spinal anesthesia, need for repeat surgery before the start of study treatment, abnormal or excessive bleeding experienced during surgery, and inability to take oral medication.</p></sec><sec id="Sec4"><title>Assessments</title><p>Thromboembolic events included asymptomatic or symptomatic DVT&#x02014;confirmed by venography at the end of study treatment&#x02014;and symptomatic and diagnosed PE. Additional imaging techniques used to confirm suspected DVT or PE included ultrasonography, computerized tomography scanning, pulmonary scintigraphy, or pulmonary arteriography.</p><p>Major bleeding was defined as fatal bleeding; clinically overt bleeding accompanied by a decrease in hemoglobin of &#x0003e;2&#x000a0;g/dL or requiring transfusion with &#x0003e;800&#x000a0;mL of blood; retroperitoneal, intracranial, intraocular, or intrathecal bleeding; or bleeding requiring repeat surgery. Clinically relevant nonmajor (CRNM) bleeding was defined as bleeding that did not meet the criteria for major bleeding, but was characterized by hematoma &#x02265;5&#x000a0;cm in diameter, epistaxis or gingival bleeding in the absence of external factors lasting &#x02265;5&#x000a0;min, gastrointestinal bleeding, gross hematuria persistent after 24&#x000a0;h of onset, or any other bleeding deemed clinically significant by the investigator. Minor bleeding was any bleeding event that was not considered a major or CRNM bleeding event. Thromboembolic events were assessed by the blinded Thromboembolic Event Assessment Committee and bleeding events by the Bleeding Event Assessment Committee.</p><p>Blood sampling was performed at presurgical evaluation, pretreatment (postsurgery), predose on day 7, predose on completion of treatment, and at a follow-up examination 25 to 35&#x000a0;days after the last dose of study drug. All biomarker assessments for D-dimer, F<sub>1+2</sub>, and SFMC were performed and measured at a central laboratory (SRL Inc., Tokyo, Japan). D-dimer was measured by a latex agglutination assay using the LATECLE D-dimer test kit (Kainos Laboratories, Inc., Tokyo, Japan; upper limit of detection, 1.0&#x000a0;&#x003bc;g/mL); data were expressed as D-dimer units. Assessment of F<sub>1+2</sub> was performed via ELISA (Fibinostika, Organon Teknika BV, The Netherlands; normal detection range 69&#x02013;229 pmol/L) [<xref ref-type="bibr" rid="CR15">15</xref>] and assessment of SFMC was performed via a latex immunoturbidimetric assay (upper limit of detection, 6.1&#x000a0;&#x003bc;g/mL) [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p>Treatment compliance was assessed by clinical interview with patients and by remaining drugs collected.</p></sec><sec id="Sec5"><title>Statistical analysis</title><p>The primary efficacy endpoint&#x02014;the proportion of patients who experienced at least 1 thromboembolic event from the start of treatment to venography&#x02014;was assessed in the full analysis set of patients, those who received &#x02265;1 dose of study drug and who underwent interpretable venography. Baseline data and safety results were analyzed in the safety set&#x02014;patients who received &#x02265;1 dose of study drug and had safety data collected after the start of treatment. Biomarker results were analyzed in the pharmacodynamic set&#x02014;patients who received &#x02265;1 dose of study drug, had no protocol violations, had compliance rates of &#x02265;80%, and had &#x02265;1 biomarker measurement (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Distribution of patients in the pooled data analyses. <sup><italic>a</italic></sup>The safety analysis set included all enrolled patients who received study drug, had posttreatment safety data, and did not have significant GCP violations. <sup><italic>b</italic></sup>The full analysis set included all patients receiving &#x02265;1 dose of study drug and excluded patients with significant GCP violations or with inadequate venography. <sup><italic>c</italic></sup>Multiple answers were allowed; patients falling under multiple categories were counted once for each category. <sup><italic>d</italic></sup>The per-protocol set included patients in the FAS and excluded patients with violations of inclusion or exclusion criteria, violation of rules for prohibited concomitant drugs/treatment, or &#x0003c;80% compliance with study drug. GCP&#x02009;=&#x02009;good clinical practice; FAS = full analysis set; THA&#x02009;=&#x02009;total hip arthroplasty; TKA&#x02009;=&#x02009;total knee arthroplasty</p></caption><graphic xlink:href="12959_2016_121_Fig1_HTML" id="MO1"/></fig>
</p><p>The number of VTE events and number of bleeding events across the 2 trials were added. The Farrington-Manning method [<xref ref-type="bibr" rid="CR17">17</xref>] was used to derive the difference in VTE incidence. The SCORE method [<xref ref-type="bibr" rid="CR18">18</xref>] was used to calculate 95% confidence intervals (CIs) for both VTE and bleeding events. For analysis of coagulation biomarkers, summary statistics were calculated by group and time.</p><p>Paired comparisons between groups were performed using chi squared or Wilcoxon rank sum testing with a significance level set to 5%. All statistical tests were conducted as 2-sided tests.</p></sec></sec><sec id="Sec6" sec-type="results"><title>Results</title><sec id="Sec7"><title>Patients</title><p>There were no significant differences in baseline characteristics between the combined treatment groups from the 2 trials (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Overall, patients were predominantly women (83%) of a mean age of 68&#x000a0;years. The primary disease was most frequently osteoarthritis (88%). A total of 1326 patients were enrolled; this analysis included 657 patients who received edoxaban 30&#x000a0;mg once daily and 650 patients who received enoxaparin 20&#x000a0;mg twice daily. Patient disposition was similar between the 2 trials (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Patient demographics and baseline characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>Edoxaban<break/>30&#x000a0;mg QD<break/>
<italic>N</italic>&#x02009;=&#x02009;657</th><th>Enoxaparin<break/>20&#x000a0;mg BID<break/>
<italic>N</italic>&#x02009;=&#x02009;650</th><th>
<italic>P</italic> value</th></tr></thead><tbody><tr><td>Female, n (%)</td><td>552 (84.0)</td><td>527 (81.1)</td><td char="." align="char">0.161<sup>a</sup>
</td></tr><tr><td>Age, years, mean (min&#x02013;max)</td><td>68.3 (36&#x02013;84)</td><td>68.1 (24&#x02013;84)</td><td char="." align="char">0.760<sup>b</sup>
</td></tr><tr><td>Body weight, kg, mean (min&#x02013;max)</td><td>58.7 (40&#x02013;124)</td><td>58.8 (40&#x02013;98)</td><td char="." align="char">0.848<sup>b</sup>
</td></tr><tr><td>Creatinine clearance, mL/min, mean (min&#x02013;max)</td><td>82.1 (30.6&#x02013;242.9)</td><td>81.7 (31.0&#x02013;209.7)</td><td char="." align="char">0.804<sup>b</sup>
</td></tr><tr><td colspan="4">Primary disease, n (%)</td></tr><tr><td>&#x02003;Osteoarthritis</td><td>582 (88.6)</td><td>563 (86.6)</td><td char="." align="char" rowspan="3">0.270<sup>c</sup>
</td></tr><tr><td>&#x02003;Rheumatoid arthritis</td><td>42 (6.4)</td><td>46 (7.1)</td></tr><tr><td>&#x02003;Other</td><td>35 (5.0)</td><td>41 (6.3)</td></tr></tbody></table><table-wrap-foot><p>
<italic>BID</italic> twice daily, <italic>QD</italic> once daily</p><p>
<sup>a</sup>Chi square test</p><p>
<sup>b</sup>t test</p><p>
<sup>c</sup>Wilcoxon test</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec8"><title>Primary efficacy endpoint</title><p>The composite of asymptomatic DVT and symptomatic DVT or PE occurred in 28 of 554 patients who received edoxaban (5.1%) and 58 of 543 patients who received enoxaparin (10.7%), <italic>P</italic> &#x0003c;0.001 (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). Thromboembolic events were primarily asymptomatic DVT.<fig id="Fig2"><label>Fig. 2</label><caption><p>Primary efficacy endpoint &#x02013; incidence of VTE. <sup>a</sup>Chi square test. VTE&#x02009;=&#x02009;venous thromboembolism</p></caption><graphic xlink:href="12959_2016_121_Fig2_HTML" id="MO2"/></fig>
</p></sec><sec id="Sec9"><title>Biomarkers</title><p>Plasma levels of the coagulation biomarker D-dimer are shown in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3a</xref> and Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. Mean D-dimer concentrations substantially increased after surgery but before treatment. After treatment, mean D-dimer levels (standard deviation [SD]) decreased significantly more in the edoxaban-treated than the enoxaparin-treated patients, respectively, both on day 7 (4.4 [2.1] vs 5.5 [2.6] &#x003bc;g/mL) and at the end of treatment (days 11&#x02013;14) (5.4 [2.5] vs 6.2 [3.1] &#x003bc;g/mL), <italic>P</italic> &#x0003c;0.0001 for both. Median values and ranges are provided in Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1.<fig id="Fig3"><label>Fig. 3</label><caption><p>Levels of coagulation biomarkers. <bold>a</bold> D-dimer; <bold>b</bold> Prothrombin fragments 1&#x02009;+&#x02009;2 (F<sub>1+2</sub>); <bold>c</bold> Soluble fibrin monomer complex (SFMC). Open circles mark mean; horizontal lines indicate median; boxes represent 25&#x02013;75%; capped lines represent 10 and 90%; <sup>*</sup>&#x02009;=&#x02009;<italic>P</italic> &#x0003c;0.001 (Wilcoxon test)</p></caption><graphic xlink:href="12959_2016_121_Fig3_HTML" id="MO3"/></fig>
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Mean plasma concentrations of coagulation biomarkers at various time points after total knee or total hip arthroplasty</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="2"/><th colspan="2">Preoperation</th><th colspan="2">Pretreatment</th><th colspan="2">Day 7<sup>a</sup>
</th><th colspan="2">End of treatment (days 11&#x02013;14)<sup>a</sup>
</th></tr><tr><th>n</th><th>Mean (SD)</th><th>n</th><th>Mean (SD)</th><th>n</th><th>Mean (SD)</th><th>n</th><th>Mean (SD)</th></tr></thead><tbody><tr><td rowspan="2">D-dimer (&#x003bc;g/mL)</td><td>Edoxaban</td><td>535</td><td>0.73 (0.82)</td><td>535</td><td>9.42 (12.56)</td><td>532</td><td>4.43<sup>b</sup> (2.08)</td><td>528</td><td>5.37<sup>b</sup> (2.52)</td></tr><tr><td>Enoxaparin</td><td>527</td><td>0.78 (0.96)</td><td>527</td><td>10.92 (16.23)</td><td>480</td><td>5.53 (2.56)</td><td>472</td><td>6.23 (3.12)</td></tr><tr><td rowspan="2">F<sub>1+2</sub> (pmol/L)</td><td>Edoxaban</td><td>535</td><td>273.9 (150.6)</td><td>535</td><td>479.7 (741.8)</td><td>532</td><td>362.8<sup>b</sup> (164.2)</td><td>528</td><td>292.1<sup>b</sup> (167.6)</td></tr><tr><td>Enoxaparin</td><td>527</td><td>277.8 (160.9)</td><td>527</td><td>633.2 (3234.9)</td><td>480</td><td>463.3 (185.6)</td><td>472</td><td>379.6 (174.4)</td></tr><tr><td rowspan="2">SFMC (&#x003bc;g/mL)</td><td>Edoxaban</td><td>535</td><td>5.62 (17.86)</td><td>535</td><td>32.25 (40.47)</td><td>532</td><td>5.71<sup>b</sup> (9.76)</td><td>528</td><td>6.15<sup>b</sup> (10.72)</td></tr><tr><td>Enoxaparin</td><td>527</td><td>4.81 (8.42)</td><td>527</td><td>34.72 (45.62)</td><td>480</td><td>6.82 (13.99)</td><td>472</td><td>7.23 (11.78)</td></tr></tbody></table><table-wrap-foot><p>
<italic>F</italic>
<sub><italic>1+2</italic></sub> thrombin fragments 1&#x02009;+&#x02009;2, <italic>SD</italic> standard deviation, <italic>SFMC</italic> soluble fibrin monomer complex</p><p>
<sup>a</sup>Predose</p><p>
<sup>b</sup>
<italic>P</italic> vs enoxaparin &#x0003c;0.0001 (Wilcoxon test)</p></table-wrap-foot></table-wrap>
</p><p>Mean F<sub>1+2</sub> concentrations increased after surgery and decreased following treatment with edoxaban or enoxaparin. The observed decrease in F<sub>1+2</sub> following edoxaban treatment was larger relative to the decrease observed with enoxaparin treatment (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3b</xref> and Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). The mean F<sub>1+2</sub> concentrations (SD) in edoxaban-treated and enoxaparin-treated patients, respectively, on day 7 of treatment were 363 (164) vs 463 (186) pmol/L and at the end of treatment were 292 (168) vs 380 (174) pmol/L, <italic>P</italic> &#x0003c;0.0001 for both. Median values and ranges are provided in Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1.</p><p>Mean SFMC concentrations rose after surgery and showed a larger decrease following edoxaban treatment relative to enoxaparin treatment (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3c</xref> and Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). The mean SFMC concentrations (SD) in edoxaban and enoxaparin patients, respectively, on day 7 were 5.7 (9.8) vs 6.8 (14.0) &#x003bc;g/mL and at the end of treatment were 6.2 (10.7) vs 7.2 (11.8), <italic>P</italic> &#x0003c;0.0001 for both. Median values and ranges are provided in Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1.</p><p>Assessment of plasma concentrations of biomarkers was performed in patients stratified by the presence or absence of VTE and the presence or absence of major or CRNM bleeding. Values followed a similar trend for patients with and without VTE and for edoxaban and enoxaparin treatment for D-dimer and F<sub>1+2</sub> (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). Values for SFMC were similar between edoxaban and enoxaparin treatments and were numerically elevated for patients with VTE relative to those who did not have VTE. Values for D-dimer, F<sub>1+2</sub>, and SFMC followed a similar trend for patients with and without CRNM and for treatment with edoxaban and enoxaparin (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>).<table-wrap id="Tab3"><label>Table 3</label><caption><p>Mean plasma concentrations of coagulation biomarkers at various time points after total knee or total hip arthroplasty in patients with and without VTE</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="2"/><th colspan="2">Preoperation</th><th colspan="2">Pretreatment</th><th colspan="2">Day 7<sup>a</sup>
</th><th colspan="2">End of treatment (days 11&#x02013;14)<sup>a</sup>
</th></tr><tr><th>n</th><th>Mean (SD)</th><th>n</th><th>Mean (SD)</th><th>n</th><th>Mean (SD)</th><th>n</th><th>Mean (SD)</th></tr></thead><tbody><tr><td colspan="10">Patients without VTE</td></tr><tr><td rowspan="2">&#x02003;D-dimer (&#x003bc;g/mL)</td><td>Edoxaban</td><td>526</td><td>0.73 (0.84)</td><td>526</td><td>9.33 (12.54)</td><td>521</td><td>4.40 (2.09)</td><td>511</td><td>5.35 (2.49)</td></tr><tr><td>Enoxaparin</td><td>485</td><td>0.77 (0.94)</td><td>485</td><td>10.28 (14.82)</td><td>443</td><td>5.38 (2.32)</td><td>430</td><td>6.00 (2.96)</td></tr><tr><td rowspan="2">&#x02003;F<sub>1+2</sub> (pmol/L)</td><td>Edoxaban</td><td>526</td><td>273.6 (150.3)</td><td>526</td><td>478.6 (748.6)</td><td>521</td><td>361.5 (164.6)</td><td>511</td><td>293.5 (169.3)</td></tr><tr><td>Enoxaparin</td><td>485</td><td>273.9 (139.3)</td><td>485</td><td>614.6 (3357.3)</td><td>443</td><td>457.9 (183.8)</td><td>430</td><td>372.6 (166.6)</td></tr><tr><td rowspan="2">&#x02003;SFMC (&#x003bc;g/mL)</td><td>Edoxaban</td><td>526</td><td>5.38 (17.34)</td><td>526</td><td>31.21 (39.32)</td><td>521</td><td>5.55 (9.04)</td><td>511</td><td>6.31 (11.22)</td></tr><tr><td>Enoxaparin</td><td>485</td><td>4.33 (6.04)</td><td>485</td><td>31.87 (43.53)</td><td>443</td><td>6.22 (11.68)</td><td>430</td><td>6.94 (10.80)</td></tr><tr><td colspan="10">Patients with VTE</td></tr><tr><td rowspan="2">&#x02003;D-dimer (&#x003bc;g/mL)</td><td>Edoxaban</td><td>28</td><td>0.75 (0.86)</td><td>28</td><td>8.40 (9.17)</td><td>24</td><td>4.56 (1.52)</td><td>23</td><td>5.46 (2.88)</td></tr><tr><td>Enoxaparin</td><td>58</td><td>0.90 (0.97)</td><td>58</td><td>16.96 (24.17)</td><td>47</td><td>7.06 (3.86)</td><td>49</td><td>8.41 (3.78)</td></tr><tr><td rowspan="2">&#x02003;F<sub>1+2</sub> (pmol/L)</td><td>Edoxaban</td><td>28</td><td>258.4 (117.4)</td><td>28</td><td>483.3 (220.5)</td><td>24</td><td>352.9 (128.3)</td><td>23</td><td>248.7 (86.31)</td></tr><tr><td>Enoxaparin</td><td>58</td><td>309.8 (273.2)</td><td>58</td><td>824.8 (959.3)</td><td>47</td><td>531.2 (213.6)</td><td>49</td><td>444.5 (222.0)</td></tr><tr><td rowspan="2">&#x02003;SFMC (&#x003bc;g/mL)</td><td>Edoxaban</td><td>28</td><td>8.90 (21.23)</td><td>28</td><td>52.19 (48.89)</td><td>24</td><td>8.10 (18.70)</td><td>23</td><td>4.77 (2.38)</td></tr><tr><td>Enoxaparin</td><td>58</td><td>8.36 (18.17)</td><td>58</td><td>63.67 (56.12)</td><td>47</td><td>12.31 (26.32)</td><td>49</td><td>9.85 (17.73)</td></tr></tbody></table><table-wrap-foot><p>
<italic>F</italic>
<sub><italic>1+2</italic></sub> thrombin fragments 1&#x02009;+&#x02009;2, <italic>SD</italic> standard deviation, <italic>SFMC</italic> soluble fibrin monomer complex, <italic>VTE</italic> venous thromboembolism</p><p>
<sup>a</sup>Predose</p></table-wrap-foot></table-wrap>
<table-wrap id="Tab4"><label>Table 4</label><caption><p>Mean plasma concentrations of coagulation biomarkers at various time points after total knee or total hip arthroplasty in patients with and without major or clinically relevant nonmajor bleeding</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="2"/><th colspan="2">Preoperation</th><th colspan="2">Pretreatment</th><th colspan="2">Day 7<sup>a</sup>
</th><th colspan="2">End of treatment (days 11&#x02013;14)<sup>a</sup>
</th></tr><tr><th>n</th><th>Mean (SD)</th><th>n</th><th>Mean (SD)</th><th>n</th><th>Mean (SD)</th><th>n</th><th>Mean (SD)</th></tr></thead><tbody><tr><td colspan="10">Patients without major or CRNM bleeding</td></tr><tr><td rowspan="2">&#x02003;D-dimer (&#x003bc;g/mL)</td><td>Edoxaban</td><td>627</td><td>0.75 (0.99)</td><td>627</td><td>9.75 (12.95)</td><td>597</td><td>4.43 (2.07)</td><td>578</td><td>5.38 (2.49)</td></tr><tr><td>Enoxaparin</td><td>626</td><td>0.78 (0.92)</td><td>626</td><td>10.72 (15.39)</td><td>552</td><td>5.47 (2.53)</td><td>517</td><td>6.15 (3.00)</td></tr><tr><td rowspan="2">&#x02003;F<sub>1+2</sub> (pmol/L)</td><td>Edoxaban</td><td>627</td><td>275.4 (148.0)</td><td>627</td><td>484.7 (736.0)</td><td>597</td><td>361.1 (162.2)</td><td>578</td><td>291.7 (163.2)</td></tr><tr><td>Enoxaparin</td><td>626</td><td>276.4 (153.3)</td><td>626</td><td>617.3 (2975.3)</td><td>552</td><td>463.4 (192.4)</td><td>517</td><td>378.2 (171.4)</td></tr><tr><td rowspan="2">&#x02003;SFMC (&#x003bc;g/mL)</td><td>Edoxaban</td><td>627</td><td>5.72 (17.49)</td><td>627</td><td>32.69 (40.46)</td><td>597</td><td>5.66 (9.50)</td><td>578</td><td>6.30 (11.18)</td></tr><tr><td>Enoxaparin</td><td>626</td><td>4.80 (8.14)</td><td>626</td><td>34.71 (45.40)</td><td>552</td><td>6.88 (13.49)</td><td>517</td><td>7.12 (11.43)</td></tr><tr><td colspan="10">Patients with major or CRNM bleeding</td></tr><tr><td rowspan="2">&#x02003;D-dimer (&#x003bc;g/mL)</td><td>Edoxaban</td><td>30</td><td>0.52 (0.27)</td><td>30</td><td>8.73 (11.84)</td><td>15</td><td>4.53 (1.70)</td><td>9</td><td>6.29 (3.52)</td></tr><tr><td>Enoxaparin</td><td>24</td><td>0.89 (1.29)</td><td>24</td><td>8.95 (9.28)</td><td>14</td><td>5.24 (1.86)</td><td>10</td><td>8.40 (6.20)</td></tr><tr><td rowspan="2">&#x02003;F<sub>1+2</sub> (pmol/L)</td><td>Edoxaban</td><td>30</td><td>264.5 (108.3)</td><td>30</td><td>440.3 (430.4)</td><td>15</td><td>371.5 (141.5)</td><td>9</td><td>325.0 (140.9)</td></tr><tr><td>Enoxaparin</td><td>24</td><td>265.8 (113.4)</td><td>24</td><td>526.2 (714.4)</td><td>14</td><td>470.3 (143.3)</td><td>10</td><td>449.0 (120.6)</td></tr><tr><td rowspan="2">&#x02003;SFMC (&#x003bc;g/mL)</td><td>Edoxaban</td><td>30</td><td>3.41 (1.82)</td><td>30</td><td>30.28 (44.24)</td><td>15</td><td>4.03 (1.06)</td><td>9</td><td>6.42 (3.20)</td></tr><tr><td>Enoxaparin</td><td>24</td><td>5.05 (4.38)</td><td>24</td><td>26.66 (32.86)</td><td>14</td><td>4.08 (1.49)</td><td>10</td><td>7.84 (4.31)</td></tr></tbody></table><table-wrap-foot><p>
<italic>CNRM</italic> clinically relevant nonmajor, <italic>F</italic>
<sub><italic>1+2</italic></sub> thrombin fragments 1&#x02009;+&#x02009;2, <italic>SD</italic> standard deviation, <italic>SFMC</italic> soluble fibrin monomer complex</p><p>
<sup>a</sup>Predose</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec10"><title>Safety</title><p>There were no significant differences in the incidence of bleeding events during the trial between groups treated with edoxaban or enoxaparin (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). Combined major and CRNM bleeding events occurred in 4.6% of edoxaban-treated and 3.7% of enoxaparin-treated patients (<italic>P</italic>&#x02009;=&#x02009;0.427). The incidence of adverse events (AEs) was slightly lower in the edoxaban group (66%) than the enoxaparin group (75%). There were no differences in the frequency of serious AEs between the treatment groups [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>].<fig id="Fig4"><label>Fig. 4</label><caption><p>Incidence of major and CRNM bleeding events. <sup><italic>a</italic></sup>Chi square test; CI&#x02009;=&#x02009;confidence interval; CRNM&#x02009;=&#x02009;clinically relevant nonmajor</p></caption><graphic xlink:href="12959_2016_121_Fig4_HTML" id="MO4"/></fig>
</p></sec></sec><sec id="Sec11" sec-type="discussion"><title>Discussion</title><p>The risk of VTE increases after knee or hip arthroplasty [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. As shown in this pooled analysis of two phase 3 trials 11 to 14&#x000a0;days after surgery for TKA or THA, the incidence of VTE was significantly lower in patients administered once-daily oral edoxaban 30&#x000a0;mg (5.1%) than in those receiving twice-daily subcutaneous enoxaparin 20&#x000a0;mg (10.7%), <italic>P</italic> &#x0003c;0.001. Coagulation biomarkers D-dimer, F<sub>1+2</sub>, and SFMC each increased immediately after surgery. Over the course of 11 to 14&#x000a0;days, levels of the coagulation biomarkers were significantly lower after treatment with the DOAC edoxaban relative to the LMWH enoxaparin. In contrast, the frequency of bleeding events in the pooled results did not significantly differ.</p><p>Doses and timing used in this study are consistent with the Japanese standard of care for enoxaparin. Japanese patients typically have a lower body weight relative to their Western counterparts. Although the dose of enoxaparin used was low (2000&#x000a0;IU, twice daily), this is the recommended dose specific to Japan for prevention of VTE [<xref ref-type="bibr" rid="CR4">4</xref>]. Prophylactic, subcutaneous enoxaparin doses of 40&#x000a0;mg once daily or 30&#x000a0;mg twice daily in males weighing &#x0003e;57&#x000a0;kg are associated with increased enoxaparin exposure and increased bleeding risk. Administration of LMWH 2 to 4&#x000a0;h postoperatively has been associated with higher rates of major bleeding relative to administration at 12 to 48&#x000a0;h postoperatively [<xref ref-type="bibr" rid="CR19">19</xref>]. The Japanese standard of care calls for initiation of enoxaparin 24 to 36&#x000a0;h following surgery.</p><p>The results of STARS E-3 (TKA) [<xref ref-type="bibr" rid="CR5">5</xref>] and STARS J-V (THA) [<xref ref-type="bibr" rid="CR6">6</xref>] followed the same pattern as the pooled results reported here, with an incidence of VTE after surgery of 7.4 and 2.4% for edoxaban and 13.9 and 6.9% for enoxaparin in the 2 trials, respectively, and no significant differences in bleeding events. In a phase 2, dose-finding study in Japan, mean levels of D-dimer and F<sub>1+2</sub> increased after TKA and remained above baseline for 11 to 14&#x000a0;days in placebo-treated patients, whereas treatment with edoxaban after surgery significantly reduced levels of the coagulation biomarkers in a dose-dependent manner [<xref ref-type="bibr" rid="CR20">20</xref>]. In a retrospective study of patients undergoing TKA in Japan, patients treated with edoxaban 15&#x000a0;mg once daily showed significant reductions in D-dimer relative to enoxaparin 20&#x000a0;mg twice daily or fondaparinux 1.5&#x000a0;mg once daily over a 2-week period following surgery [<xref ref-type="bibr" rid="CR21">21</xref>].</p><p>Edoxaban directly and selectively inhibits FXa, which is part of both the intrinsic and extrinsic coagulation pathways that lead to generation of thrombin and clot formation [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. One molecule of FXa can catalyze the formation of approximately 1000 thrombin molecules [<xref ref-type="bibr" rid="CR23">23</xref>]. In contrast, LMWHs target FXa indirectly and affect multiple targets in the coagulation pathway [<xref ref-type="bibr" rid="CR23">23</xref>]. The direct and selective targeting of FXa by edoxaban may account for the significantly greater reduction in coagulation biomarkers, which translates to reduced rates of VTE.</p><p>Limitations of this analysis include that it is post hoc and that it combines data from 2 different studies. However, the studies were very similar in anticoagulant treatment regimens and patient characteristics. In addition, for the coagulation biomarker results, pooling of results was required to obtain sufficient data to perform statistical comparisons between treatments. It also should be noted that edoxaban is approved only in Japan for VTE prophylaxis and is not approved for this indication in Europe or the United States.</p></sec><sec id="Sec12" sec-type="conclusion"><title>Conclusions</title><p>In conclusion, the biomarker results for the pooled analysis of the TKA and THA trials may suggest stronger anticoagulant activity with once-daily oral edoxaban 30&#x000a0;mg than twice-daily, subcutaneous enoxaparin 20&#x000a0;mg following lower limb orthopedic surgery, although the initial timing of edoxaban or enoxaparin administration differed. The 2 treatments were associated with similar rates of bleeding events.</p></sec></body><back><app-group><app id="App1"><sec id="Sec13"><title>Additional file</title><p>
<media position="anchor" xlink:href="12959_2016_121_MOESM1_ESM.docx" id="MOESM1"><label>Additional file 1: Table S1.</label><caption><p>Median and range of plasma concentrations of coagulation biomarkers at various time points after total knee or total hip arthroplasty. (DOCX 14 kb)</p></caption></media>
</p></sec></app></app-group><glossary><title>Abbreviations</title><def-list><def-item><term>AE</term><def><p>Adverse event</p></def></def-item><def-item><term>CRNM</term><def><p>Clinically relevant nonmajor</p></def></def-item><def-item><term>DOAC</term><def><p>Direct oral anticoagulant</p></def></def-item><def-item><term>DVT</term><def><p>Deep vein thrombosis</p></def></def-item><def-item><term>F<sub>1+2</sub></term><def><p>Prothrombin fragments 1&#x02009;+&#x02009;2</p></def></def-item><def-item><term>FXa</term><def><p>Factor Xa</p></def></def-item><def-item><term>LMWH</term><def><p>Low-molecular-weight heparin</p></def></def-item><def-item><term>PE</term><def><p>Pulmonary embolism</p></def></def-item><def-item><term>SD</term><def><p>Standard deviation</p></def></def-item><def-item><term>SFMC</term><def><p>Soluble fibrin monomer complex</p></def></def-item><def-item><term>THA</term><def><p>Total hip arthroplasty</p></def></def-item><def-item><term>TKA</term><def><p>Total knee arthroplasty</p></def></def-item><def-item><term>VTE</term><def><p>Venous thromboembolism</p></def></def-item></def-list></glossary><ack><title>Acknowledgements</title><p>Daiichi Sankyo, the study sponsor, was involved in the design of the study and the collection and analysis of the data. Medical writing and editorial support was provided by Elizabeth Rosenberg, PhD; and Terri Schochet, PhD; of AlphaBioCom, LLC (King of Prussia, PA).</p><sec id="FPar1"><title>Funding</title><p>This study was sponsored by Daiichi Sankyo Co., Ltd. (Tokyo, Japan).</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p>The datasets generated during and/or analysed during the current study are not publicly available due to concerns regarding preserving the privacy of individual study participants, but are available from the corresponding author upon reasonable request.</p></sec><sec id="FPar3"><title>Authors&#x02019; contributions</title><p>YK, TF, SF, TK, KI, and ST were involved in the concept and design of the study, interpretation of the data, critical revising of the manuscript, and provided final approval to submit the manuscript for publication. KA was involved in analysis of the data, critical review of the mansucript, and provided final approval to submit the manuscript for publication.</p></sec><sec id="FPar4"><title>Competing interests</title><p>YK has been a consultant for Daiichi Sankyo and Toyama Chemical. TF has been a consultant for Daiichi Sankyo, Bayer, Astellas, GlaxoSmithKline, Kaken, and Ono Pharmaceutical Company; served on the speakers&#x02019; bureau for Daiichi Sankyo; and received royalties from Century Medical and Showa Ikakogyo. SF has been a consultant for Daiichi Sankyo, Astellas, and GlaxoSmithKline. ST has been a consultant for Daiichi Sankyo and GlaxoSmithKline. TK, KI, and KA are employees of Daiichi Sankyo Co., Ltd.</p></sec><sec id="FPar5"><title>Consent for publication</title><p>Not applicable.</p></sec><sec id="FPar6"><title>Ethics approval and consent to participate</title><p>The studies were performed in accordance with the provisions of the Declaration of Helsinki, Guidelines for Good Clinical Practice, and other related regulations. The protocols were approved by institutional review boards at each study center, and written informed consent was obtained from all patients prior to randomization.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geerts</surname><given-names>WH</given-names></name><name><surname>Bergqvist</surname><given-names>D</given-names></name><name><surname>Pineo</surname><given-names>GF</given-names></name><name><surname>Heit</surname><given-names>JA</given-names></name><name><surname>Samama</surname><given-names>CM</given-names></name><name><surname>Lassen</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Prevention of venous thromboembolism: American College Of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition)</article-title><source>Chest</source><year>2008</year><volume>133</volume><fpage>381S</fpage><lpage>453</lpage><pub-id pub-id-type="doi">10.1378/chest.08-0656</pub-id><pub-id pub-id-type="pmid">18574271</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>JCS Joint Working Group</collab></person-group><article-title>Guidelines for the diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (JCS 2009)</article-title><source>Circ J</source><year>2011</year><volume>75</volume><fpage>1258</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1253/circj.CJ-88-0010</pub-id><pub-id pub-id-type="pmid">21441695</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Lixiana<sup>(R)</sup> Tablets [package insert]. Daiichi Sankyo Co. Ltd.; Tokyo. 2014.</mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">Lovenox<sup>(R)</sup> (enoxaparin sodium injection) for subcutaneous and intravenous use. [Package insert]. Sanofi-Aventis U.S. LLC; Bridgewater. 2013.</mixed-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuji</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>CJ</given-names></name><name><surname>Fujita</surname><given-names>S</given-names></name><name><surname>Kawai</surname><given-names>Y</given-names></name><name><surname>Nakamura</surname><given-names>M</given-names></name><name><surname>Kimura</surname><given-names>T</given-names></name><etal/></person-group><article-title>Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial</article-title><source>Thromb Res</source><year>2014</year><volume>134</volume><fpage>1198</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1016/j.thromres.2014.09.011</pub-id><pub-id pub-id-type="pmid">25294589</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuji</surname><given-names>T</given-names></name><name><surname>Fujita</surname><given-names>S</given-names></name><name><surname>Kawai</surname><given-names>Y</given-names></name><name><surname>Nakamura</surname><given-names>M</given-names></name><name><surname>Kimura</surname><given-names>T</given-names></name><name><surname>Fukuzawa</surname><given-names>M</given-names></name><etal/></person-group><article-title>Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V</article-title><source>Thromb J</source><year>2015</year><volume>13</volume><fpage>27</fpage><pub-id pub-id-type="doi">10.1186/s12959-015-0057-x</pub-id><pub-id pub-id-type="pmid">26269694</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuji</surname><given-names>T</given-names></name><name><surname>Fujita</surname><given-names>S</given-names></name><name><surname>Kawai</surname><given-names>Y</given-names></name><name><surname>Nakamura</surname><given-names>M</given-names></name><name><surname>Kimura</surname><given-names>T</given-names></name><name><surname>Kiuchi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Safety and efficacy of edoxaban in patients undergoing hip fracture surgery</article-title><source>Thromb Res</source><year>2014</year><volume>133</volume><fpage>1016</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.thromres.2014.03.009</pub-id><pub-id pub-id-type="pmid">24680549</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adam</surname><given-names>SS</given-names></name><name><surname>Key</surname><given-names>NS</given-names></name><name><surname>Greenberg</surname><given-names>CS</given-names></name></person-group><article-title>D-dimer antigen: current concepts and future prospects</article-title><source>Blood</source><year>2009</year><volume>113</volume><fpage>2878</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1182/blood-2008-06-165845</pub-id><pub-id pub-id-type="pmid">19008457</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pulivarthi</surname><given-names>S</given-names></name><name><surname>Gurram</surname><given-names>MK</given-names></name></person-group><article-title>Effectiveness of d-dimer as a screening test for venous thromboembolism: an update</article-title><source>N Am J Med Sci</source><year>2014</year><volume>6</volume><fpage>491</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.4103/1947-2714.143278</pub-id><pub-id pub-id-type="pmid">25489560</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wells</surname><given-names>PS</given-names></name><name><surname>Anderson</surname><given-names>DR</given-names></name><name><surname>Rodger</surname><given-names>M</given-names></name><name><surname>Forgie</surname><given-names>M</given-names></name><name><surname>Kearon</surname><given-names>C</given-names></name><name><surname>Dreyer</surname><given-names>J</given-names></name><etal/></person-group><article-title>Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis</article-title><source>N Engl J Med</source><year>2003</year><volume>349</volume><fpage>1227</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa023153</pub-id><pub-id pub-id-type="pmid">14507948</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aronson</surname><given-names>DL</given-names></name><name><surname>Stevan</surname><given-names>L</given-names></name><name><surname>Ball</surname><given-names>AP</given-names></name><name><surname>Franza</surname><given-names>BR</given-names><suffix>Jr</suffix></name><name><surname>Finlayson</surname><given-names>JS</given-names></name></person-group><article-title>Generation of the combined prothrombin activation peptide (F1-2) during the clotting of blood and plasma</article-title><source>J Clin Invest</source><year>1977</year><volume>60</volume><fpage>1410</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1172/JCI108902</pub-id><pub-id pub-id-type="pmid">410831</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Misaki</surname><given-names>T</given-names></name><name><surname>Kitajima</surname><given-names>I</given-names></name><name><surname>Kabata</surname><given-names>T</given-names></name><name><surname>Tani</surname><given-names>M</given-names></name><name><surname>Kabata</surname><given-names>C</given-names></name><name><surname>Tsubokawa</surname><given-names>T</given-names></name><etal/></person-group><article-title>Changes of the soluble fibrin monomer complex level during the perioperative period of hip replacement surgery</article-title><source>J Orthop Sci</source><year>2008</year><volume>13</volume><fpage>419</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1007/s00776-008-1266-y</pub-id><pub-id pub-id-type="pmid">18843455</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Clexane&#x000ae; for Subcutaneous Injection Kit 2000IU [Package Insert (Ver. 8), in Japanese]. Sanofi-Aventis K.K; Tokyo. 2012.</mixed-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cockcroft</surname><given-names>DW</given-names></name><name><surname>Gault</surname><given-names>MH</given-names></name></person-group><article-title>Prediction of creatinine clearance from serum creatinine</article-title><source>Nephron</source><year>1976</year><volume>16</volume><fpage>31</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1159/000180580</pub-id><pub-id pub-id-type="pmid">1244564</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacCallum</surname><given-names>PK</given-names></name><name><surname>Thomson</surname><given-names>JM</given-names></name><name><surname>Poller</surname><given-names>L</given-names></name></person-group><article-title>Effects of fixed minidose warfarin on coagulation and fibrinolysis following major gynaecological surgery</article-title><source>Thromb Haemost</source><year>1990</year><volume>64</volume><fpage>511</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">2084936</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamano</surname><given-names>A</given-names></name><name><surname>Umeda</surname><given-names>M</given-names></name><name><surname>Ueno</surname><given-names>Y</given-names></name><name><surname>Tanaka</surname><given-names>S</given-names></name><name><surname>Mimuro</surname><given-names>J</given-names></name><name><surname>Sakata</surname><given-names>Y</given-names></name></person-group><article-title>Latex immunoturbidimetric assay for soluble fibrin complex</article-title><source>Clin Chem</source><year>2005</year><volume>51</volume><fpage>183</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1373/clinchem.2004.040360</pub-id><pub-id pub-id-type="pmid">15514091</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farrington</surname><given-names>CP</given-names></name><name><surname>Manning</surname><given-names>G</given-names></name></person-group><article-title>Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk</article-title><source>Stat Med</source><year>1990</year><volume>9</volume><fpage>1447</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1002/sim.4780091208</pub-id><pub-id pub-id-type="pmid">2281232</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newcombe</surname><given-names>RG</given-names></name></person-group><article-title>Interval estimation for the difference between independent proportions: comparison of eleven methods</article-title><source>Stat Med</source><year>1998</year><volume>17</volume><fpage>873</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0258(19980430)17:8&#x0003c;873::AID-SIM779&#x0003e;3.0.CO;2-I</pub-id><pub-id pub-id-type="pmid">9595617</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strebel</surname><given-names>N</given-names></name><name><surname>Prins</surname><given-names>M</given-names></name><name><surname>Agnelli</surname><given-names>G</given-names></name><name><surname>Buller</surname><given-names>HR</given-names></name></person-group><article-title>Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery?</article-title><source>Arch Intern Med</source><year>2002</year><volume>162</volume><fpage>1451</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1001/archinte.162.13.1451</pub-id><pub-id pub-id-type="pmid">12090880</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuji</surname><given-names>T</given-names></name><name><surname>Fujita</surname><given-names>S</given-names></name><name><surname>Tachibana</surname><given-names>S</given-names></name><name><surname>Kawai</surname><given-names>Y</given-names></name></person-group><article-title>A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty</article-title><source>J Thromb Haemost</source><year>2010</year><volume>8</volume><fpage>2458</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1111/j.1538-7836.2010.04021.x</pub-id><pub-id pub-id-type="pmid">20723033</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sasaki</surname><given-names>H</given-names></name><name><surname>Ishida</surname><given-names>K</given-names></name><name><surname>Shibanuma</surname><given-names>N</given-names></name><name><surname>Tei</surname><given-names>K</given-names></name><name><surname>Tateishi</surname><given-names>H</given-names></name><name><surname>Toda</surname><given-names>A</given-names></name><etal/></person-group><article-title>Retrospective comparison of three thromboprophylaxis agents, edoxaban, fondaparinux, and enoxaparin, for preventing venous thromboembolism in total knee arthroplasty</article-title><source>Int Orthop</source><year>2014</year><volume>38</volume><fpage>525</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1007/s00264-013-2132-x</pub-id><pub-id pub-id-type="pmid">24100922</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furugohri</surname><given-names>T</given-names></name><name><surname>Isobe</surname><given-names>K</given-names></name><name><surname>Honda</surname><given-names>Y</given-names></name><name><surname>Kamisato-Matsumoto</surname><given-names>C</given-names></name><name><surname>Sugiyama</surname><given-names>N</given-names></name><name><surname>Nagahara</surname><given-names>T</given-names></name><etal/></person-group><article-title>DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles</article-title><source>J Thromb Haemost</source><year>2008</year><volume>6</volume><fpage>1542</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">18624979</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turpie</surname><given-names>AG</given-names></name></person-group><article-title>Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2007</year><volume>27</volume><fpage>1238</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.107.139402</pub-id><pub-id pub-id-type="pmid">17379841</pub-id></element-citation></ref></ref-list></back></article>